Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Enzymes
- Defense/Military
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6880
License Grant
The Israelite Licensee entered into a Research and License Agreement with the Israelite Licensor, the technology transfer arm of Israel’s Weizmann Institute of Science, pursuant to which Yeda is using its technology to design a next generation of Glucocerebrosidase (GCD) for the treatment of Gaucher Disease that can be expressed using our plant cell system.
License Property
In connection with the upfront and milestone payments made under the Pfizer license and supply agreement, the sub-licensee has accrued a sublicense fee equal to $1.6 million payable to the academic institution from whom it licensed certain technology relating to taligluceraze alfa.
Taliglucerase alfa is used as an enzyme replacement therapy for the treatment of Gaucher disease. Taliglucerase alfa is our proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human cells that is mutated or deficient in patients with Gaucher disease.
Field of Use
The rights granted apply to the healthcare industry relating to replacement therapy.
IPSCIO Record ID: 4019
License Grant
The Licensor and the Licensee entered into a License and supply Agreement pursuant to which the Licensee was granted an exclusive, worldwide License to develop and commercialize Taliglucerase Alfa. Under the terms and conditions of the Agreement, the Licensor retained the right to commercialize Taliglucerase Alfa in Israel.
License Property
The Licensor will manufacture all of the Taliglucerase Alfa needed for all purposes under the Agreement and the Licensee will purchase the Taliglucerase Alfa from the Licensor.
Taliglucerase Alfa may have the potential for increased potency and efficacy in certain parameters compared to the existing enzyme replacement therapy for Gaucher disease.
Field of Use
The field of use relates to the medical industry.
IPSCIO Record ID: 248345
License Grant
Licensor, a non-profit organization, grants the Israeli Licensee a license under Patent Rights to make, have made, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods, in the Field within the Territory and during the Term. The license granted is non-exclusive.
License Property
Licensor has rights in the inventions titled Production of Lysosomal Enzymes in Plant-Based Expression Systems.
Lysosomal storage diseases are a group of about 50 rare inherited metabolic disorders that result from defects in lysosomal function.[1] Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling. This process requires several critical enzymes. If one of these enzymes is defective, because of a mutation, the large molecules accumulate within the cell, eventually killing it.
Field of Use
The Field means all uses.
IPSCIO Record ID: 204322
License Grant
Licensor grants to the English Licensee an exclusive license, with the right to grant sublicenses, under all Licensed Technology, to Develop, make, use, sell, offer for sale and import Compound and Products, in each case, solely in the Field and in the Territory.
Licensor grants a license, with the right to sublicense, in accordance with the terms of the Trademark License Agreement, to use the Licensor Trademark(s) in such country(ies) in the Territory in connection with the making, having made, use, sale, offering for sale, importation, packaging, distributing and promoting of Product in the Field and in such country(ies) in the Territory.
License Property
The Compound means migalastat, and includes any compounds with alternative names but with the same chemical structure as Migalastat, and any metabolites, prodrugs, isomers and enantiomers, excluding the isomer/enantiomer “1-deoxynorjirimycin†or “(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triolâ€, esters, salts, hydrates, solvates, and polymorphs, whether alone or in a mixture.
Migalastat, trade name Galafold (formerly known as Amigal) is a drug for the treatment of Fabry disease, a rare genetic disorder. Amigal, is an orally-administered, small molecule pharmacological chaperone for the treatment of Fabry disease.
Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. Beginning in childhood, this buildup causes signs and symptoms that affect many parts of the body.
Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of the Product in combination with ERT or enzyme replacement therapy.
The specific treatment available for Fabry disease (FD) is enzyme replacement therapy (ERT) with agalsidase alfa or beta.
IPSCIO Record ID: 25861
License Grant
The agreement relates to the rights of our company to have the license related to research conducted and to be conducted at the Weizmann Institute of Science, under the supervision of Professor Yair Reisner of the Department of Immunology, and relates to an invention comprising methods of organ transplantation utilizing developing nephric and other tissues.
Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
